INO-4800 is a DNA vaccine containing the full sequence for the SARS-CoV-2 Spike (S) protein in development for immunization against COVID-19.A214475 Early in vitro studies using HEK-293T cells demonstrated that the transfection of INO-4800 results in the expression of S protein by human cells.A214475, A214478 Follow up studies in both BALB/c mice and Hartley guinea pigs demonstrated the ability of INO-4800 to induce both humoral and T cell-mediated immunity against SARS-CoV-2, including in the lungs. Furthermore, the antibodies produced were capable of inhibiting the binding of SARS-CoV-2 to the ACE2 receptor, which is thought to be critical for host cell entry.A214475
A Phase 1 clinical trial for INO-4800 in the U.S. (NCT04336410) was started on April 3, 2020, with an expected completion date of July 2021.L14372 A Phase 1/2 clinical trial through South Korea's Seoul National University Hospital was announced on June 4, 2020, and expected to start later in the month.L14375
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.